Chemotherapy-induced Neutropenia
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Neutropenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-08-18Clinical Trial Update: Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects [Phase 1]
A Phase 1 trial evaluating tolerability and PK/PD of GW003 in healthy subjects, conducted to support chemotherapy-induced neutropenia treatm…
-
CLINICAL_TRIALS trial_result · 2017-08-11Clinical Trial Update: Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients [Phase 1]
A Phase 1 study evaluating the safety and preliminary activity of an rHSA/GCSF fusion protein in breast cancer patients with chemotherapy-in…
-
CLINICAL_TRIALS trial_result · 2017-07-18Clinical Trial Update: Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein [Phase 2]
Phase 2 study evaluating a recombinant human serum albumin–granulocyte colony-stimulating factor fusion protein for chemotherapy-induced neu…
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim [Phase 3]
A Phase III trial comparing LA-EP2006 to pegfilgrastim in chemotherapy-induced neutropenia and breast cancer completed with results posted i…
-
FDA approval · 2017-06-21FDA Approved: GRANIX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for GRANIX (TBO-FILGRASTIM) submitted by Cephalon, LLC. The approval updates GRANIX's regulatory sta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-15Clinical Trial Update: Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® [Phase 3]
Phase III study comparing LA-EP2006 to Neulasta in preventing chemotherapy-induced neutropenia in breast cancer; the trial was completed and…
-
FDA approval · 2017-02-02FDA Approved: GRANIX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for GRANIX (tbo-filgrastim) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS research · 2016-11-30Clinical Trial Update: The Effect of Acupoint Massotherapy on Relieving Chemotherapy-induced Myelosupression [NA]
This clinical trial update discusses evaluating acupoint massotherapy to relieve chemotherapy-induced myelosuppression in cancer patients, i…
-
CLINICAL_TRIALS trial_result · 2016-10-24Clinical Trial Update: Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer [Phase 2]
This update reports results from a Phase 2 dose-finding trial of Empegfilgrastim for preventing chemotherapy-induced neutropenia in breast c…
-
CLINICAL_TRIALS trial_result · 2016-03-15Clinical Trial Update: Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers [Phase 1]
This Phase 1 study evaluated how food affects the safety, tolerability, and pharmacokinetics of EC-18 administered orally in healthy volunte…
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors [Phase 1]
Phase 1 safety and pharmacokinetic study of GW003 in metastatic tumors, including patients with chemotherapy-induced neutropenia.
-
CLINICAL_TRIALS trial_result · 2016-01-27Clinical Trial Update: Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers [Phase 1]
This document reports the completion of a Phase 1 study evaluating the safety, tolerability and pharmacokinetics of EC-18 following oral adm…
-
CLINICAL_TRIALS trial_result · 2016-01-11Clinical Trial Update: A Safety and PK Study of EC-18 in Healthy Subjects [Phase 1]
This Phase 1 study reports safety and pharmacokinetic data for EC-18 in healthy subjects, evaluating tolerability and PK parameters in a fir…
-
FDA approval · 2015-09-23FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for NEULASTA (pegfilgrastim) submitted by Amgen, Inc.
-
CLINICAL_TRIALS trial_result · 2015-04-07Clinical Trial Update: Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim [Phase 3]
Phase III study comparing EP2006 to filgrastim in patients with chemotherapy-induced neutropenia and breast cancer, assessing efficacy and s…
-
FDA approval · 2014-12-23FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for NEULASTA (pegfilgrastim) filed by Amgen, Inc, allowing changes to the product as described i…
-
CLINICAL_TRIALS trial_result · 2014-10-01Clinical Trial Update: Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia [Phase 2]
A Phase II study of DA-3031 (PEG-G-CSF) for chemotherapy-induced neutropenia has completed.
-
CLINICAL_TRIALS trial_result · 2014-10-01Clinical Trial Update: Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia [Phase 3]
Phase III trial evaluating DA-3031, a pegylated G-CSF, for chemotherapy-induced neutropenia has been completed.
-
CLINICAL_TRIALS trial_result · 2013-11-06Clinical Trial Update: GCPGC in Chemotherapy-induced Neutropenia [Phase 2, Phase 3]
A completed Phase 2/Phase 3 trial of GCPGC for chemotherapy-induced neutropenia is reported.
-
CLINICAL_TRIALS research · 2012-07-11Clinical Trial Update: Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients [Phase 1]
This document reports a Phase 1 pharmacokinetic and pharmacodynamic study of pegfilgrastim in chemotherapy patients.
-
FDA approval · 2011-06-03FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental Biologics License Application for NEULASTA (pegfilgrastim) from Amgen, resulting in labeling updates approve…
-
CLINICAL_TRIALS trial_result · 2011-05-13Clinical Trial Update: G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer [Phase 2]
Phase 2 trial evaluating whether granulocyte colony-stimulating factor can prevent chemotherapy-induced neutropenia in women with breast can…
-
CLINICAL_TRIALS trial_result · 2011-01-27Clinical Trial Update: A Study Comparing Pegylated Filgrastim and Filgrastim in Support for Chemotherapy [Phase 3]
A Phase 3 trial comparing pegfilgrastim with filgrastim in cancer patients receiving chemotherapy has completed. The study evaluated efficac…
-
CLINICAL_TRIALS trial_result · 2010-02-03Clinical Trial Update: Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF) [Phase 3]
A Phase 3 trial evaluating the safety and efficacy of recombinant human G-CSF for chemotherapy-induced neutropenia has completed.
-
CLINICAL_TRIALS trial_result · 2007-08-30Clinical Trial Update: Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia [Phase 2]
Phase 2 trial evaluating Mannan-binding lectin substitution in MBL-deficient children with chemotherapy-induced neutropenia has been complet…